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1. Introduction 
Nearly 80% patients of pancreatic cancer (PC) have impaired glucose metabolism, either 
frank diabetes or impaired glucose tolerance (IGT)1, 2 and the majority of diabetes associated 
with PC is diagnosed either concomitantly or during the two years before the diagnosis of 
PC3 Karmody and Kyle reported that PC was diagnosed within one year from the onset of 
the diabetes in 40 out of 51 patients (78.4%)4 According to Gullo et al.5, diabetes in patients 
with PC is frequently (56.1%) of the recent onset type and is presumably caused by the 
tumor. In this study, in 43.9% of the patients, the diagnosis of diabetes preceeded the 
diagnosis of PC by three years and in 37.2% it was five or more years. In a more recent 
study, the diagnosis of PC and diabetes was made concomitantly or shortly before the 
tumor diagnosis in 65% of the patients 6. Presently, a number of investigators consider 
diabetes to be a clinical manifestation of PC rather than a risk factor for the disease. This 
view is in sharp contrat to views that diabetes is a predisposing factor for PC. In many 
retrospective case-control and prospective cohort studies, an association between 
longstanding diabetes and an increased rate of subsequent death from PC was indicated 7-9. 
In recent studies, however, when the latency period between the onset of diabetes and PC 
was considered, the issue became muddled. In some studies, when the patients with short 
latency periods were excluded from the sample size, the relative risk of diabetes for PC was 
markedly diminished3-5. In another population-based case control study, a significant 
positive trend in risk for PC was detected (p=0.016) in patients with diabetes diagnosed ten 
or more years prior to cancer detection10.The meta-analysis of more than 20 epidemiologic 
studies indicated the relative risk of PC for diabetics diagnosed at least five years prior to 
the diagnosis of cancer as 2.011.  In two prospective cohort studies with more than 20 years 
follow-up, an increased risk was found among subjects with high post-load plasma glucose 
levels 12, 13. In the latter study, the risk was 2.2-fold higher for participants whose post-load 
glucose level was at least 200 mg/dl at baseline compared with those with the levels equal 
or less than 119 mg/dl. These studies evidently show that glucose intolerance may preceed 
the onset of PC rather than just being a consequence. 
The major problem of such epidemiological studies is that the exact onset time of both 
diabetes and PC is obscure and insidious. The non-insulin-dependent diabetes mellitus may 
take more than seven years before it is clinically diagnosed 14. The latency of PC is also 
unclear, and the development of some cancers seems to take ten years15  or even longer16. 
Undiagnosed diabetes or PC may have proceeded for many years without diagnosis. For 
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these reasons, estimation of the exact duration needed to conclude that the diabetes 
occurred before or after the development of PC is difficult. 
The incidental pancreatic cancer detection indicates that this cancer can remain silent for a 
considerable time or grow very slowly 17. Nevertheless, the notion that diabetes is a 
predisposing factor for PC remains questionable. Data gained from experimental pancreatic 
cancer model unquestionably indicate that the IGT is associated with the development of 
pancreatic cancer. We performed the following study to understand reasons for the 
development of diabetes in pancreatic cancer. 
Eight-week-old out bred Syrian Golden hamsters (SGH) of the Eppley colony were used. 
They were housed in the centralized Comparative Medicine Animal Facilities, an AAALAC 
International accredited animal facility, in plastic cages on corncob bedding (Bed-O-Cobs, 
The Anderson Cob Co., Maumee, OH) under standard laboratory conditions (temperature, 
21 ± 2°C; humidity, 40±5%; light/dark cycle, 12 hr/12 hr; 10x air changes/hr). They were 
fed a commercial diet (Wayne Lab Blox, Allied Mills, Chicago, IL) and had free access to tap 
water. The maintenance and humane treatment of the animals followed the guidelines of the 
UNMC Animal Care and Use Committee. 
For the determination of glucose metabolism, five randomly selected 8-week-old male SGH 
with an average weight of 100 g were treated with the potent pancreatic carcinogen, N-
nitrosobis(2-oxopropyl)amine (BOP) at a dose of 10 mg/kg body weight once a weak for 
four weeks. The same number of animals served as controls. Ten weeks after the last BOP 
injection, at the time generally proliferative and hyperplastic lesions appears, glucose 
tolerance was determined in all hamsters as reported 18. Following the test the pancreas of 
all hamsters was examined histologically.  
The presence of Insulin and glucagon assay in pancreatic juice and plasma was investigated 
in thirty 8-week-old male SGH with an average weight of 100g, who were treated with BOP 
as above. Thirty hamsters of the same age and weights were served as controls. In each 
group, the insulin content of pancreatic juice and plasma were assayed in 10 hamsters each 
at 12, 16 and 20 weeks after the last BOP injection as reported 19, 20.  
From our tumor archieve, the pancreatic tissue of 30 SGH with tumors induced by BOP at a 
dose of 10 mg/kg body weight weekly for six weeks were examined 
immunohistochemically using antibodies to insulin, glucagon, somatostatin and PP with a 
multilabeling technique, developed in our laboratory 21. Sixty seven surgically removed 
human pancreatic cancer specimens from our previous study 22 were also subjected to 
immunohistochemical examination for the expression of insulin, glucagon, somatostatin and 
PP as above.  
The results of these experiments showed that at 10 weeks after BOP treatment plasma insulin 
level did not change compared to that in untreated control hamsters, whereas the glucose level 
increased significantly at 120 minutes (Fig. 1). Histologically focal or multi-focal ductal and 
ductular hyperplasia and in one hamster ductal in situ carcinoma were found. As in our 
previous studies, intrainsular ductular proliferation were found in all hamsters.  
Insulin assay in pancreatic juice and plasma: As summarized in Table 1, although at week 12 
the plasma insulin concentration did not differ from the control value, it decreased by one-
half at week 16 but was significantly lower at week 20. On the contrary the level of insulin in 
pancreatic juice increased successively and was significantly decreased significantly and 
successively while juice insulin level conversely increased significantly by time (Table 1). 
The glucagon level in plasma did not change significantly at either point, whereas its level 
increased significantly and successively and was the highest at 20 week (Table 2). 
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Proliferative and hyperplastic ductal lesions were found at week 12 and 16 and a few in situ 
carcinomas and a microcarcinoma at week 20. A remarkably large number of endocrine cells 
(primarily β-cells) were found in hyperplastic ducts and in the microcarcinoma (Fig. 2), as 
well as some of hybrid type containing endocrine granules and mucin.  
Immunohistochemically in all hyperplastic, premalignant and malignant lesions in human 
tissues, scattered or generally a large number of endocrine cells, composed primarily of 
insulin and glucagon, and less frequently somatostatin cells were found in the basal layer, 
but sometimes within the papillary fonts (Fig. 2). Insulin immunoreactivity was also present 
in the luminal content of hyperplastic ducts and malignant glands. 
 
 
Fig. 1. Glucose tolerance test in SGH treated with BOP weekly for 6 weeks (red) and in 
untreated controls (blue) 
 
Week Plasma Juice 
12 6.07±1.96 4.28±1.40 
16 3.02±1.67 5.07±2.05 
20 2.52±0.12* 8.43±2.40* 
*p<0.05 compared to control values 
Table 1. Insulin Levels (μU/ml) 
 
Week Plasma Juice 
12 0.62±0.07 25.8±4.40* 
16 3.02±1.67 35.4±2.19* 
20 2.52±0.12 39.4±3.10* 
*p<0.001 compared to control values 
Table 2. Levels of Glucagon (ng/ml)  
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Fig. 2. Endocrine cells in pancreatic cancer. a) hamster adenocarcinoma. Insulin (brown), 
glucagon (blue), somatostatin (red). Multilabeling technique x65. B) Insulin cells in 
papillary fond and in the basal layer of the malignant epithelial cells of a human 
intraductal cancer. x50. c) insulin cells in human pancreatic cancer. x50; d) Insulin cells in 
proliferative ductal lesion in a hamster. x50; e) a large number of endocrine cells in human 
pancreatic cancer. insulin (blue); glucagon (brown); somatostatin (red). Multilabeling 
technique x50), f. endocrine cells covering the whole length of the basal layer of a tumor 
in a patient. X45.  
Similar to the findings in the hamster tissue, insulin, glucagon and, less frequently, 
somatostatin cells were found in hyperplastic, but in extremely large numbers in well 
differentiated malignant glandular structures in human PC. In many areas the number of 
endocrine  cells exceeded the number of malignant cells in glandular structures (Fig. 2). 
Remarkably, in the lumen of several malignant glands, many cells and debris 
immunoreactive with anti-insulin were identified (Fig. 3). 
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Fig. 3. Cells and debris immunoreactive with  anti-insulin in the lumen of malignant gland 
structures. β cells are also present in the base of the epithelium (arrows). X65 
Experimental models have opened avenues for studying areas of research that are 
impossible to obtain from humans. Among the existing pancreatic cancer model, SGH has 
provided the most relevant model for translational research. Morphologically, the wide 
spectrum of human pancreatic cancer, including the rare tumors, is reproducible in this 
species. Most human pancreatic cancer-associated antigens, including blood group antigens, 
as well as carbohydrate antigens are also expressed in cancers induced in hamsters. Most 
genetic mutations, methylation  or deletions found in human pancreatic cancer, including 
the K-ras, p16INK4A, DPC4/SMAD4, DCC and FHIT are also detected in hamster pancreatic 
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cancer25. Remarkably, the deletion of chromosome Y, frequently found in human pancreatic 
cancer 23, 24 occurs also in the hamster tumor. Moreover, among other existing PC models, 
including transgenic mouse models, the hamster model is the only model that shows insulin 
secretion abnormality, occurring in over 80% of PC patients. 
Based on these similarities, the model offered a useful tool to understand the existing 
controversial view on the association between type 2 diabetes and PC. Although SGH are 
not prone to diabetes, under certain diet they present pre-diabetic condition such as 
peripheral insulin resistance, which, as in humans, can be controlled by Metformin26. 
Because in this model initial alteration occurs within the islets by formation of intrainsular 
ductular structures, which progressively leads to the development of cancer that destroys 
the islet 27, studies were performed to explore the effect of such alteration on glucose 
metabolism.  Ahrén and Andrén-Sandberg, were the first to demonstrate the abnormality in 
glucose tolerance occurs at the very early stages of carcinogenesis18. In their study, where 
the glucose tolerance and insulin secretion during the development of pancreatic cancer was 
examined, the glucose tolerance and glucose-stimulated insulin secretion were found to be 
normal at 6, 12, and 18 weeks after start of carcinogen treatment compared with age-
matched saline-injected controls. By contrast, after 24, 30, and 42 weeks, at which time 
proliferative and neoplastic lesions develop, an exaggerated plasma-glucose response and a 
concomitant impaired plasma-insulin response occurred during the glucose infusion (P < 
0.05). Hence, it was conclude that the development of pancreatic cancer in this model is 
accompanied by glucose intolerance and impaired insulin secretion, and that these effects 
occur concomitantly with the development of cancer. In the present study using the same 
experimental protocol confirmed the development of IGT (Fig. 1). At the time of 
proliferative and hyperplastic ductal lesions.  
Reasons for examining the pancreatic juice during pancreatic cancer development was based 
on our findings of insulin-like and growth hormone-like substances in pancreatic juice of 
untreated hamsters19. Literature search revealed that this discovery was not unique to 
hamsters and has been reported in pancreatic juice of humans and laboratory species 28-34 
supporting the assumption for the existence of an insuloacinar portal system to regulate 
exocrine pancreatic functions by islet hormones35. The question on the mechanism of 
whether insulin enters into the ductal system by passive or active mechanism has remained 
illusive. Since CCK is a powerful stimulant for the release of insulin and somatostatin34, the 
greater effect of CCK infusion in eliciting a higher concentration of immunoreactive insulin 
and somatostatin in the pancreatic juice34 indicated that the hormones in the juice derive 
directly from the islets to the ductules29. This view is further supported by our electron 
microscopical findings that revealed the likelihood of the direct route of insulin into the 
ductal lumen, as insulin granules were found in large numbers in peri ductal and peri 
vascular spaces, suggesting that insulin secretion occurs into both blood vessels and ductal 
lumen36. Hence, It appears that in the normal condition pancreatic hormones is secreted into 
blood vessels and ductal system possibly in a controlled defined proportion. The 
physiological importance of insulin secretion via ductal system as a potent growth factor for 
gastrointestinal epithelium has been discussed by us elsewhere36. 
As stated earlier, the initial development of ductular structures within the islets with 
gradual proliferation, malignant alteration and gradual replacement of the islets 27suggested 
alteration in insulin secretion. The development of mixed ductular-insular structures, 
suggesting intimate communication between islet cells and ductal cells prompted us to 
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examine the pancreatic juice of hamsters during tumor development. In a study, we 
measured the concentrations of insulin, glucagon, somatostatin, and islet amyloid 
polypeptide (IAPP) in plasma and secretin-stimulated pancreatic juice at 12 and 27 weeks 
after the treatment of hamsters with BOP20. At 12 weeks after BOP, plasma glucagon levels 
were significantly increased. An exaggerated plasma-glucose response were observed at 27 
but not at 12 weeks after BOP. Plasma IAPP concentrations, but not glucagon or 
somatostatin, were elevated at 27 weeks. Tissue concentrations of IAPP were substantially 
reduced in BOP-treated hamsters at 27 weeks. The study, nevertheless, showed that islet 
hormone changes accompany the early development of pancreatic tumors in this model. 
Thus, the hormone changes and apparent insulin resistance resemble the metabolic changes 
found in humans with pancreatic cancer20. 
In the present study, a dramatic increase of insulin and glucagon levels was found in 
pancreatic juice of hamsters during pancreatic carcinogenesis indicating an alteration in islet 
function causing a shift in insulin secretion. Indeed, in both humans and hamsters islet cells 
during cancer development undergo alterations, including transdifferentiation of hormone 
producing cells into duct-like elements23 that could explain the reduction in the level of 
plasma insulin. The level of insulin in pancreatic juice, however, is maintained and further 
increased by another event. In the hamster model and in human pancreatic cancer subjects 
as well, normal ducts, but more often altered ducts and especially malignant glandular 
structures show a large number of endocrine cells immunoreactive to ani-insulin and anti-
glucagon antibodies, embedded within the epithelium (27, and Fig 2). In some cases, the 
number of endocrine cells exceeded the number of the malignant epithelial cells (Fig 2). 
Within the malignant epithelium as well as in the lumen of several malignant glands many 
cells immunoreactive with anti-insulin were identified (Fig. 3). The finding suggested than 
insulin-containing cells, produced by malignant glands, are expelled into the glandular 
lumen, as are malignant cells, and thus into the pancreatic juice. Remarkably, we could not 
find any study examining the presence of hormones in pancreatic juice of pancreatic cancer 
patients, although, as stated earlier, endocrine hormones in pancreatic juice has been 
recognized many years ago in patients without pancreatic cancer. 
The above information along with our current results let us conclude that the induction of 
proliferative and malignant lesions in the pancreas is associated with IGT, which also occurs 
in the majority of human cases. In fact, a study in Japan has shown that the incidence of IGT 
in PC patients was dependent on the size of cancer; in patients with tumor size >2.1 cm, the 
incidence of IGT was 56%, in tumors of 2.0 cm in size, it was 36%, in those with 1.1-2 cm, it 
was 39% and in 7 patients with tumors <1 cm, it was 28%. In the latter case, the abnormality 
was the only clinically detectable abnormality 37. Remarkably, the determination of IGT has 
not yet been adapted as a routine test in the United States possibly awaiting additional 
validating data to be presented.  
2. Conclusion 
In SGH the development of PC is associated with IGT, as has also been suggested in 
humans. 2) In the normal pancreas, insulin is also secreted into pancreatic juice, both in 
humans and in animals. 3) The reduced level of insulin in blood but its increased 
concentration in pancreatic juice during pancreatic carcinogenesis is likely responsible for 
the IGT and diabetes, and 4) the development of IGT, along with hypersecretion of insulin 
in pancreatic juice could present early marker for PC. 
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